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Abstract
Critical illness in patients with pre-existing diabetes 
frequently causes deterioration in glycaemic control. 
Despite the prevalence of diabetes in patients admit-
ted to hospital and intensive care units, the ideal 
management of hyperglycaemia in these groups is 
uncertain. There are data that suggest that acute 
hyperglycaemia in critically ill patients without diabetes 
is associated with increased mortality and morbidity. 
Exogenous insulin to keep blood glucose concentrations 
< 10 mmol/L is accepted as standard of care in this 
group. However, preliminary data have recently been 
reported that suggest that chronic hyperglycaemia may 
result in conditioning, which protects these patients 
against damage mediated by acute hyperglycaemia. 
Furthermore, acute glucose-lowering to < 10 mmol/L 
in patients with diabetes with inadequate glycaemic 
control prior to their critical illness appears to have 
the capacity to cause harm. This review focuses on 
glycaemic control in critically ill patients with type 2 
diabetes, the potential for harm from glucose-lowering 
and the rationale for personalised therapy.
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Core tip: With diabetes increasing in prevalence, 
the optimal management of glycaemia in critically ill 
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patients with pre-existing diabetes remains unknown. 
Recent data has highlighted therapeutic uncertainties 
specific to these patients with suggestions that targeted 
blood glucose concentrations may benefit from consi­
deration of a patient’s premorbid glucose state. In 
patients with uncontrolled type 2 diabetes, it may be 
safer to target blood glucose concentrations between 
10­14 mmol/L, however definitive studies of critically ill 
patients with poorly controlled diabetes are required. 
In contrast, in patients with CIAH, or those with well-
controlled diabetes (HbA1c < 7.0) have data supporting 
a more conservative target (6-10 mmol/L).
Kar P, Jones KL, Horowitz M, Deane AM. Management 
of critically ill patients with type 2 diabetes: The need for 
personalised therapy. World J Diabetes 2015; 6(5): 693-706 
Available from: URL: http://www.wjgnet.com/1948-9358/full/
v6/i5/693.htm  DOI: http://dx.doi.org/10.4239/wjd.v6.i5.693
INTRODUCTION
Patients with diabetes mellitus may develop an acute 
severe illness that necessitates a level of care that can 
only be provided within an intensive care unit (ICU)[1]. 
In the majority of critically ill patients with pre-existing 
diabetes, the pathophysiological response to the acute 
illness or injury, and/or the treatments involved, may 
lead to deterioration in glycaemic control. Despite 
the high and increasing prevalence of diabetes (both 
within the community and in the critically ill), the 
optimal management of glycaemia in critically ill pati-
ents with pre-existing diabetes remains unknown. 
However, recent data has highlighted the therapeutic 
uncertainties specific to these patients.
The majority of critically ill patients with diabetes 
have type 2 diabetes[2]. The limited information 
relating to patients with type 1 diabetes precludes 
speculation as to whether management of glycaemia 
in this group should be different from that in type 2 
diabetes. Accordingly, this review focuses on critically 
ill patients with type 2 diabetes addressing issues 
including prevalence, potential rationale for harm and 
evidence for personalised therapy.
PREVALENCE
In the community type 2 diabetes occurs frequently 
with global health expenditure estimated at US $376 
billion in 2010, which is expected to rise to US $490 
billion by 2030 due to increasing prevalence[3,4]. In 
Australia it is estimated over the last 15 years, the 
prevalence has increased from 8.5% to 12.0%[5]. 
There is a substantial variation in the prevalence 
of diabetes between countries, peaking in Nauru 
(31%)[6]. Factors relating to the increase in prevalence 
include increasing obesity, increasing age and racial 
region. A limitation in estimating prevalence is that 
many patients remain unaware of their diagnosis. 
For example, the estimated prevalence in the United 
States is 13% of the population, of which 40% is 
unrecognised or undiagnosed[7].
Diagnosis of diabetes
The prevalence of recognised and unrecognised 
diabetes varies according to the definitions used, 
as well as the location and the populations studied. 
The current diagnostic criteria used by the American 
Diabetes Association (ADA) involves one of the 
following; an HbA1c ≥ 6.5, a fasting glucose ≥ 7 
mmol/L, a 2 h post glucose tolerance test following a 
75 g oral glucose load of ≥ 11.1 mmol/L, or a random 
blood glucose ≥ 11.1 mmol/L with symptoms of 
hyperglycaemia[8]. These criteria were ratified by the 
World Health Organization (WHO) in 2011[9]. 
Given each test (HbA1c, fasting, postprandial or 
random blood glucose) reflects different physiological 
phenomena, different populations may be diagnosed 
when using each criterion[10,11]. Each diagnostic test 
has advantages and disadvantages. Both the fasting 
glucose and 2 h post glucose tolerance test are 
established standards, relatively rapid and easy to 
perform, and predict microvascular complications. 
However, these tests are subject to day-to-day 
variability, require patients to fast and only reflect 
glucose homeostasis at a single point in time[12]. HbA1c 
is convenient (with no fasting required), can predict 
microvascular complications, is a better predictor 
of macrovascular disease (than fasting glucose or 2 
h post glucose tolerance test) and has low day-to-
day variability[8,12]. Additionally, as the physiological 
responses to acute illness cause deterioration in 
glycaemia, estimating glucose control prior to the acute 
illness - using markers such as HbA1c - to accurately 
determine which patients have unrecognised diabetes 
and which patients have “stress hyperglycaemia” is 
possible[13]. Weaknesses include variations amongst 
ethnic groups and age, it may be misrepresentative 
in certain medical conditions (such as certain forms of 
anaemia and haemoglobinopathies) and the need for a 
validated, standardised assay[12].
Prevalence of diabetes in hospitalised patients 
Compared to the general population, the prevalence of 
diabetes in hospitalised adult patients (i.e., admitted to 
general wards) is considered to be greater. Depending 
on the population, estimates range from between 
11%-35% of all patients (Table 1). 
Numerous studies in the critically ill have evaluated 
the prevalence of glucose intolerance (Table 1). 
However, a limitation of the studies reported is that 
investigators were unable to identify those patients 
who had so-called “stress hyperglycaemia” (or critical 
illness associated hyperglycaemia (CIAH) - the 
condition of acute glucose intolerance that is confined 
to the period of critical illness) and those who have 
unrecognised diabetes. Several studies use either 
fasting blood glucose (≥ 7 mmol/L) and/or random 
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glucose concentrations (≥ 11.1 mmol/L) for diagnosis 
of diabetes[14-16].
Investigators have also measured glycated haemo-
globin (HbA1c) on admission to identify hospitalised 
patients with unrecognised diabetes. A prospective 
observational study of 695 patients in Boston, 
Massachusetts[17], selected a cutoff HbA1c of > 6.5% 
to diagnose diabetes, with 19% of patients having 
diabetes previously diagnosed and 5% having 
undiagnosed diabetes. Another study of 971 patients 
admitted to the general medical ward of an urban 
hospital located in the Bronx, New York[18] - which may 
be assumed to admit a larger cohort of lower-income 
patients - 35% were known to have diabetes, and 
16% undiagnosed diabetes, using an HbA1c ≥ 6.5. 
In summary, the prevalence of diabetes in hospi-
talised patients varies according to geography. In the 
developed world, diabetes is more prevalent amongst 
lower socioeconomic groups[19-21]. Furthermore, diabetes 
is a risk factor for certain diseases (e.g., cardiovascular 
disease) and prevalence will be greater if a specific 
population (e.g., patients presenting with myocardial 
ischaemia) is studied[22].
Prevalence of diabetes in patients admitted to ICU
The prevalence of diabetes in patients admitted to 
the ICU is estimated to be between 12%-40% (Table 
2). Similar to the prevalence in hospitalised patients, 
the wide range reflects the definitions used and the 
population studied. Multiple single centre observational 
studies from the United States[23-25] report prevalence 
between 13% and 21%, therefore it is likely that the 
true prevalence is close to this range. More recently, 
Falciglia et al[26] undertook a retrospective cohort study 
across 173 ICUs in the United States and reported that 
30% of the 259040 patients had a history of diabetes 
according to ICD-9 codes[26]. 
A single centre, observational study from London, 
United Kingdom[27], found 16% of patients had a 
history of diabetes. A retrospective observational study 
of 4946 patients admitted to one of two hospitals in 
Melbourne and Sydney, Australia[28], reported 15% 
had diabetes. While a single, mixed medical/surgical 
ICU from Amsterdam, The Netherlands[29], found 12% 
of 5961 patients admitted had a history of diabetes. 
These data indicate that the prevalence in other 
developed countries may be similar to, or slightly less 
than, the United States. 
Data from international studies are consistent with 
this concept. Stegenga et al[30] utilised data collected as 
part of a randomised interventional study[31] to evaluate 
whether diabetes affects the outcome of sepsis in 
patients admitted to one of 164 ICUs across 11 countries 
and reported that 23% had pre-existing diabetes. In 
retrospective observational data derived from 44964 
patients admitted to one of 23 ICUs worldwide[32], 
29% had a history of diabetes documented in their 
medical records, but the prevalence varied substantially 
according to geography. For example, in an ICU from 
Geelong, Australia, the prevalence was 14%, while in 
a hospital < 100 km away (Melbourne) it was 24%, 
whereas patients admitted to Tampa Bay, United States, 
the prevalence was 39%. 
The prevalence of diabetes in the critically ill varies 
across studies. Multiple observational studies estimate 
the prevalence at 12%-30%[23-29,30,32-35]. However, these 
studies have significant limitations. Most importantly, 
the prevalence may be under represented due to 
diabetes that is either unrecognised or not documented. 
A number of interventional studies have also 
reported diabetes prevalence in ICU patients (Table 
2). Two prospective, randomised, controlled studies 
of surgical and medical ICU patients admitted into the 
ICU in Leuven, Belgium, compared an intensive insulin 
therapy (ITT, blood glucose level 4.4-6.1 mmol/L) vs 
conventional treatment (insulin started if the blood 
glucose was > 12 mmol/L and maintained between 
10-11.1 mmol/L)[36,37]. These studies reported diabetes 
at 13% and 17% respectively.
Other interventional studies include single centre[38,39] 
and multicentre trials[40-42], with the largest being in 
2009, the NICE-SUGAR (Normoglycaemia in Intensive 
Care Evaluation-Survival Using Glucose Algorithm 
Regulation) study. This was conducted across 42 ICUs 
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Table 1  Prevalence of diabetes in hospital population (chronological order)
Ref. Year R-D UR-D Total study 
patients
Location Diabetes diagnosed by Unrecognised diabetes diagnosed by




1886 Atlanta, United 
States
Admission history Fasting blood glucose ≥ 7 mmol/L
Random blood glucose ≥ 11.1 mmol/L × 2









Random blood glucose ≥ 11.1 mmol/L



























Admission history Fasting blood glucose ≥ 7 mmol/L
1May include patients with stress hyperglycaemia/critical illness associated hyperglycaemia. R-D: Recognised diabetes; UR-D: Unrecognised diabetes. 
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body of evidence suggests, chronic glucose control 
may have implications on optimal acute glucose ranges 
in the critically ill. 
Hospital and ICU prevalence of unrecognised 
diabetes can be estimated from the studies mentioned 
(Tables 1 and 2) along with other studies cited below 
(Table 3). Hospital prevalence is estimated to be 
between 5%-16%[16-18,43] and ICU prevalence between 
6%-14%[34,44]. The prevalence in patients with 
ischaemic heart disease (e.g., presenting with acute 
myocardial infarction) appears to be higher[45,46].
In two European studies, patients with an acute 
myocardial infarct and without a history of diabetes 
subsequently underwent an oral glucose tolerance 
test (OGTT) to diagnose diabetes[45,46]. The prevalence 
of diabetes was found to be over 30% at discharge, 
and between 25%-31% at 3 mo. In London (United 
Kingdom), Emergency Department patients were 
throughout Australia, New Zealand and Canada[41], 
and noted 20% of its 6029 patients with a history 
of diabetes, with the majority (92%) having type 2 
diabetes. 
It should be recognised that there are limitations to 
using data from these interventional studies. Inclusion 
into these studies usually requires hyperglycaemia 
and therefore leads to selection bias, which artificially 
increases any estimate of prevalence. The interventional 
trials estimated ICU prevalence at 13%-40%[36-42].
Prevalence of unrecognised diabetes
Patients may have diabetes that is unrecognised 
prior to admission[2]. This may not represent “stress 
hyperglycaemia” or CIAH - as the hyperglycaemia is 
chronic rather than acute. Unrecognised diabetes is 
important as it not only impacts on estimations for the 
actual prevalence of the condition, but, as a growing 
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Table 2  Prevalence of diabetes in the intensive care unit population (chronological order)
Ref. Year Study type R-D UR-D Total study 
patients
Location Recognised DM diagnosis Unrecognised diabetes 
diagnosed by
Van den Berghe et al[36] 2001 Interv 204 (13%) N/A 1548 Leuven, 
Belgium
Admission history N/A
Finney et al[27] 2003 Observ 86 (16%) N/A 523 London, United 
Kingdom
Unknown N/A
Whitcomb et al[23] 2005 Observ 574 (21%) 3951 (15%) 2713 Baltimore, 
United States
Admission history Hyperglycaemia without 
a history of DM
Van den Berghe et al[37] 2006 Interv 203 (17%) N/A 1200 Leuven, 
Belgium
Admission history N/A
Krinsely[24] 2006 Observ 1110 (21%) N/A 5365 Stamford, 
United States
Hospital records (ICD-9 
codes) for the first 2 yr 
then all available info 
N/A
Egi et al[28] 2008 Observ 728 (15%) N/A 4946 Multicentre 
(Australia)
Hospital records N/A
Treggiari et al[25] 2008 Observ 1361 (13%) N/A 10456 Seattle, United 
States
Hospital records N/A





Bronkhurst et al[38] 2008 Interv 163 (30%) N/A 537 Multicentre 
(Germany)
Unknown N/A
Del La Rosa et al[42] 2008 Interv 61 (12%) N/A 504 Medellin, 
Colombia
Admission history N/A




Preiser et al[40] 2009 Interv 203 (19%) N/A 1078 Multicentre 
(Europe)
Admission history N/A
Falciglia et al[26] 2009 Observ 77850 (30%) N/A 259040 Multicentre 
(United States)
Hospital records (ICD-9 
codes)
N/A
Stegenga et al[30] 2010 Observ 188 (23%) N/A 830 Multicentre 
(Worldwide)
Admission history N/A





Krinsely et al[33] 2011 Observ 669 (21%) N/A 3263 Multicentre 
(United States, 
Europe)
Hospital records (ICU 
clinical database)
N/A
Krinsley et al[32] 2013 Observ 12880 (29%) N/A 44964 Multicentre 
(Worldwide)
Admission history N/A
Plummer et al[34] 2014 Observ 220 (22%) 55 (6%) 1000 Adelaide, 
Australia
Admission history
Phone call to GP
HbA1c ≥ 6.5
HbA1c ≥ 6.5 without a 
history of DM
1May include patients with stress hyperglycaemia/critical illness associated hyperglycaemia. Interv: Interventional; Observ: Observational; R-D: Recognised 
diabetes; UR-D: Unrecognised diabetes; NZ: New Zealand; N/A: Not available.
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screened for diabetes via fasting blood glucose[47] and 
it was reported that 3% patients had unrecognised 
diabetes.
We recently performed a single centre observational 
study in a mixed medical/surgical ICU in Adelaide, 
Australia, and separated patients with diabetes (either 
known or unrecognised) and CIAH using HbA1c to 
accurately estimate the prevalence of each condition[34]. 
Of 1000 consecutively admitted ICU patients, 22% 
had known diabetes (5% were type 1) and 6% had 
unrecognised diabetes (HbA1c ≥ 6.5%). The absence 
of previously diagnosed diabetes was confirmed by a 
phone call to the patient’s usual local medical officer 
(general practitioner).
Subsequently, Hoang et al[44] also estimated the 
prevalence of undiagnosed diabetes in a prospective, 
observational study in a single medical ICU[44]. All 
patients with hyperglycaemia and those with known 
diabetes underwent measurement of HbA1c with 
diabetes defined as an HbA1c ≥ 6.5%. Sixty-six 
percent of the 299 patients enrolled into the study 
had a history of diabetes. Of the remaining 102 
hyperglycaemic patients without diabetes, 14% had an 
HbA1c ≥ 6.5%. 
In summary the prevalence of undiagnosed diabetes 
is difficult to determine, and as previously noted, 
depends on the definitions used and the location of 
the patient population. Current “best estimate”, albeit 
on limited data from single centres, suggest that the 
prevalence of undiagnosed diabetes is either similar to, 
or slightly greater than, the background prevalence in 
the community.




Hyperglycaemia in type 2 diabetes reflects the 
outcome of factors affecting both insulin secretion, 
with β-cell dysfunction resulting in a relative insulin 
deficiency, and insulin resistance as a result of both 
environmental and genetic factors[48,49]. However, the 
pathogenesis of hyperglycaemia in the critically ill 
patient, either with CIAH, or in those with pre-existing 
diabetes and experiencing a deterioration in their 
glucose control, is complex and poorly understood[2]. 
Patient predisposition (including insulin resistance 
and β-cell function), the underlying illness (which 
can result in catecholamine release, stimulation 
of the hypothalamic-pituitary-adrenal (HPA) axis, 
and the release of inflammatory cytokines) and the 
management involved (including glucocorticoids, 
vasopressors and nutrition) appear to be of major 
relevance[1]. 
The activation of the HPA axis and the sympathetic 
system cause the “stress” response. In the majority 
of patients “stress” hormones (including cortisol and 
catecholamines) markedly increase. In addition, the 
underlying illness may stimulate the production of 
cytokines (such as TNF-α, IL-1 and IL-6)[1,50]. These 
three components (HPA axis, sympathetic system and 
cytokine release) lead to excessive gluconeogenesis, 
glycogenolysis and insulin resistance, thereby augmen-
ting stress hyperglycaemia[50]. Glucagon is the major 
modulator of gluconeogenesis and may be stimulated 
by TNF-α, however cortisol and adrenaline (epinephrine) 
are also likely to contribute[1,51,52].
Insulin resistance is thought to occur due to a 
number of pathways. Glucose enters cells via plasma 
membrane glucose transporters (GLUTs), which 
are down regulated in times of stress, possibly due 
to the presence of TNF-α and IL-1[50]. Diminished 
glucose uptake by peripheral tissue may occur 
due to high cortisol and adrenaline (epinephrine) 
concentrations[1,53]. As discussed, acute illness results 
in increased level of cytokines, which exacerbates 
hyperglycaemia and stimulates inflammation and 
oxidative stress[1]. 
It should be considered that acute hyperglycaemia 
may represent a “protective” physiological response of 
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Table 3  Prevalence of undiagnosed diabetes in the hospital population (chronological order)
Ref. Year Diagnosis UR-D Total study 
patients
Location Patient population
Norhammer et al[45] 2002 OGTT 51 (31%) at discharge
36 (25%) at 3 mo
  164
  144
Multicentre (Sweden) Post AMI, Hospital/ICU
George et al[47] 2005 Fasting blood glucose ≥ 
7 mmol/L
13 (3%)   427 London, United Kingdom Emergency Department
Wexler et al[17] 2008 HbA1c > 6.5 33 (5%)   695 Boston, United States Hospital
Lankisch et al[46] 2008 OGTT 31 (32%) at discharge
19 (31%) at 3 mo
    96
    62
Wuppertal, Germany Post AMI, Hospital/ICU
Mazurek et al[18] 2010 HbA1c ≥ 6.5   152 (16%)   971 New York, United States Hospital
Feldman-Billard et al[16] 2013 Fasting blood glucose
≥ 7 mmol/L
156 (7%) 2141 Multicentre (France) Hospital
Plummer et al[34] 2014 HbA1c ≥ 6.5 55 (6%) 1000 Adelaide, Australia ICU
Hoang et al[44] 2014 HbA1c ≥ 6.5   14 (14%)   102 New Haven, United States Medical ICU
Ochoa et al[43] 2014 HbA1c ≥ 6.5 8 (9%)     92 Abilene, United States Hospital
UR-D: Unrecognised diabetes; OGTT: Oral Glucose Tolerance Test; AMI: Acute myocardial infarction.
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patients evaluated before and after implementation 
of an intensive glucose control policy[24], mortality 
was increased in patients with hyperglycaemia who 
were not known to have diabetes when compared 
to those with diabetes. In 2008, Egi et al[28] reported 
a retrospective study of 4946 patients in which ICU 
mortality increased with increasing mean blood 
glucose level in patients without diabetes but this 
signal of harm was absent in those with pre-existing 
diabetes[28]. 
A retrospective cohort study of 259040 ICU ad-
missions also reported an association between 
mortality and hyperglycaemia, with the relationship 
far stronger in patients without a diagnosis of diabetes 
when compared to those with pre-existing diabetes[26]. 
A retrospective analysis of a previous study[31] included 
830 patients admitted with severe sepsis (defined as 
sepsis associated with acute organ dysfunction)[30], 
and reported that hyperglycaemia was predictive of 
subsequent death in those patients not known to have 
diabetes. Additionally, a multicentre retrospective 
study of 44964 patients divided into 2 cohorts 
(with and without known diabetes)[32], reported 
increased mortality with higher mean blood glucose 
concentrations (≥ 7.8 mmol/L) when compared 
to blood glucose concentrations 4.4-7.8 mmol/L in 
patients without diabetes. In contrast, patients with 
diabetes were more likely to die when mean blood 
glucose concentrations were between 4.4-6.1 mmol/L 
when compared to patients with greater blood glucose 
concentrations (6.2-10 mmol/L).
A number of interventional studies have evaluated 
the relationship between chronic and acute hyper-
glycaemia and outcomes (Table 5). In a pooled 
analysis of studies conducted in a single centre in 
Leuven, intensive insulin therapy (ITT, aiming for blood 
glucose concentrations between 4.4-6.1 mmol/L) was 
reported to reduce mortality and morbidity in patients 
without a diagnosis of diabetes, but this was not the 
case in patients with diabetes, if anything, there was 
a trend for harm with intensive insulin therapy in 
patients with diabetes such that mortality was non-
significantly greater at a lower mean blood glucose 
range (6.1-8.3 mmol/L, 21.2% vs < 6.1 mmol/L, 
26.2%, P = 0.4 and > 8.3 mmol/L, 21.6%, P = 0.9)[54].
Subsequently, a number of interventional, ran-
domised, controlled trials, containing patients with 
diabetes, comparing ITT to more conventional glucose 
targets have been published[38-42]. A trial of 523 mixed 
(medical and surgical) ICU patients[39] reported no 
survival benefit in patients with diabetes with ITT, but 
ITT was associated with an increased prevalence of 
hypoglycaemia. The Efficacy of Volume Substitution 
and Insulin Therapy in Severe Sepsis (VISEP) study 
assigned 537 ICU patients with severe sepsis to 
either ITT or more conventional glucose targets while 
receiving either 10% pentastarch or a modified Ringers 
lactate in a two-by-two factorial study[38]. The study 
was suspended at interim analysis for safety reasons 
with ITT being associated with increases in episodes 
of severe hypoglycaemia and adverse events. De La 
Rosa et al[42] also evaluated ITT in 504 ICU patients (61 
with diabetes) and there was no mortality or morbidity 
benefit observed, but an associated increased risk of 
hypoglycaemia, when administering ITT.
In 2009, the NICE-SUGAR study compared ITT 
with conventional glucose control in 6029 ICU patients 
and established that the observations from the initial 
Leuven studies regarding ITT were not generalisable 
outside that specialised institution[41]. However, 
amongst the 1211 patients with pre-existing diabetes 
in the NICE-SUGAR study the administration of ITT 
did not appear more harmful than in patients without 
diabetes. The Glucontrol study[40], an international, 
multicentre trial involving over 1000 ICU patients was 
stopped early due to protocol violations, and it was, 
accordingly, underpowered. However, there was no 
evidence to suggest any benefit with ITT and data in 
patients with diabetes were not specifically described.
Recently a number of studies have attempted to 
measure chronic glycaemia as a dynamic (HbA1c), 
rather than a binary, variable (i.e., presence of 
diabetes - yes/no) (Table 6). Egi et al[55] performed a 
retrospective observational study of 415 patients with 
diabetes (from two Australian ICUs) in whom glycated 
haemoglobin (HbA1c) had been measured within 3 mo 
of their critical illness and evaluated how this measure 
of pre-existing glycaemia impacted on the interaction 
between acute glycaemia and mortality[55]. It was 
reported that in patients with elevated preadmission 
HbA1c levels (> 7%) the number of deaths were 
significantly fewer when blood glucose concentrations 
were > 10 mmol/L. 
Consistent with this observation, we recently measured 
HbA1c on admission and glucose concentrations for 
the first 48 h of ICU admission[34] and observed that 
acute peak glucose concentrations were associated 
with increased mortality only in patients with adequate 
premorbid glycaemic control (defined as HbA1c < 
7%), but not in patients with chronic hyperglycaemia 
(defined as an HbA1c ≥ 7%). This finding was 
also supported by Hoang et al[44] who assessed the 
prevalence of undiagnosed diabetes (i.e., HbA1c ≥ 
6.5%) among those with hyperglycaemia in a medical 
ICU. Patients with an HbA1c ≥ 6.5% were found to 
have significantly lower mortality compared to those 
with an HbA1c < 6.5% (11.7% vs 19.3%, P = 0.038), 
despite having greater glucose concentrations. 
In summary the outcomes of the largest and most 
generalisable randomised study are consistent with 
the concept that the optimal glucose concentrations 
in unselected critically ill patients are between 6-10 
mmol/L[41]. However, observational data, post-hoc 
analysis of interventional studies and studies measuring 
chronic glycaemia as a dynamic variable suggest that 
patients with pre-existing diabetes may warrant higher 
targets. Indeed, there is increasing data suggesting 
that targets should be personalised depending on both 
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hypoglycaemic episode was associated with an 
increased risk of mortality (compared with those 
without an episode of severe hypoglycaemia). Egi 
et al[61] reported mild or moderate hypoglycaemia 
was associated with mortality in critically ill patients 
- with mortality substantially increasing according to 
severity of hypoglycaemia - and patients with diabetes 
were more likely to suffer from insulin-associated 
hypoglycaemia. 
The blood glucose threshold that adverse events 
occur may be greater in patients with pre-existing 
diabetes. In a retrospective multi-centre observational 
study[32] increased mortality was reported in 12880 
patients with pre-existing diabetes who had mean 
glucose concentrations between 4.4-6.2 mmol/L. While 
the investigators were not able to differentiate between 
patients with well-controlled or poorly-controlled 
diabetes, these data support the concept that the 
threshold for “hypoglycaemia” may be increased in 
critically ill patients with diabetes when compared to 
non diabetic patients. For example, if a patient typically 
has blood glucose concentrations above 10 mmol/L, 
and, in hospital, insulin is administered to achieve 
blood glucose concentration of about 6 mmol/L, this 
may result in a “relative” hypoglycaemia. 
Glycaemic variability
Glycaemic variability (GV) describes the fluctuations 
in blood glucose concentrations, as marked fluctua-
tions may be associated with multiple adverse effects 
such as apoptosis, cytokine production and increased 
markers of oxidative stress[59]. Oxidative stress 
markers have been shown to increase with glucose 
fluctuations[62,63]. GV may be assessed by a number of 
methods. Techniques to quantify variability are reviewed 
elsewhere[64].
Multiple studies in the critically ill have established 
as an association with poor outcomes and GV[44,65-71], 
however the evidence in patients with pre-existing 
diabetes is limited and inconsistent (Table 8). In 
2006, Egi et al[65] published a retrospective, electronic 
database analysis of 7049 ICU patients in 4 centres 
around Australia, using standard deviation as a marker 
of glucose variability, and focusing on the association 
of blood glucose variability and mortality[65]. Both 
mean and standard deviation of blood glucose were 
independently associated with mortality. 
A retrospective, single center cohort study of 
patients admitted with sepsis reported that GV 
was also independently associated with increased 
mortality and importantly, that this was independent 
of hypoglycaemia and the presence of diabetes[66]. 
Another retrospective study of 3252 patients reported 
that increased GV was associated with mortality[67] 
and diabetes was associated with greater GV. A 
prospective, observational study of 42 patients used 
non-lineal dynamics to measure glycaemia in time 
series[69]. Patients underwent continuous glucose 
monitoring system measuring interstitial glucose 
concentrations every 5 min for 48 h. The authors 
reported greater variability was associated with 
increasing mortality, even in patients with diabetes. 
However, given the small cohort, these results must be 
treated with caution.
Other studies have reported no relationship between 
mortality and GV in patients with diabetes. A retro-
spective, observational study of 4084 critically ill 
patients (942 with known diabetes)[68] reported that 
GV was associated with mortality in patients without 
diabetes, but not in patients with diabetes. More 
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Table 6  Observational studies that have recorded chronic glycaemia as a dynamic variable (chronological order)
Ref. Year Study pts Study point Non diabetic patients Diabetic patients Overall message
Egi et al[55] 2011   415 Does preexisting 
hyperglycaemia modulate the 
association between glycemia 
and outcome in ICU patients 
with DM
N/A Patients with elevated preadmission 
HbA1c levels (> 7%) showed a 
mortality benefit when mean ICU 
glucose concentrations were > 10 
mmol/L
Relationship between HbA1c 
and mortality changed 
according to the levels of time-




2014 1000 Prevalence of CIAH and 
recognized/unrecognized 
DM in ICU and to evaluate 
the premorbid glycaemia on 
the association between acute 
hyperglycaemia and mortality
50% had CIAH
Risk of death inc by 
20% for each increase 
in acute glycaemia of 
1 mmol/L
Well controlled DM (HbA1c < 6%) 
and adequately controlled (DM 
6%-7%) - risk of death as per non 
diabetic patient
HbA1c ≥ 7% (insufficiently 
controlled DM) had no significance 
between mortality and acute 
glycaemia
22% had recognised DM
6% had unrecognised diabetes
Hoang et 
al[44]
2014   299 Prevalance of unrecognized 
DM amongst those with CIAH 
and the association between 
baseline glycaemia and 
mortality
102 (34%) had no 
history of DM
14/102 (14%) had 
unrecognized DM 
(diagnosed with 
HbA1c ≥ 6.5) 
197 (66%) had a history of DM Lower HbA1c had inc mortality 
(in this population of CIAH 
patients) despite lower median 
glucose values and less glucose 
variability
Mortality in HbA1c < 6.5 (19%) 
vs HbA1c ≥ 6.5 (12%), P = 0.04
Inc: Increased; Dec: Decreased; N/A: Not available. 
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recently in the study by Hoang et al[44] of 299 patients 
there was no association between GV and mortality in 
their entire cohort, however the group with diabetes 
(128 patients) had a lower rate of mortality despite 
having a higher GV. Additionally, a retrospective 
analysis of 2782 ICU patients, comparing different GV 
indices and mean glucose concentrations to predict 
mortality and ICU acquired infections[70] reported that 
while GV was associated with infections and mortality 
in patients without pre-existing diabetes, in those with 
diabetes GV was greater but was not associated with 
either mortality or infection.
In summary, there is a strong relationship between 
GV and mortality in critically ill patients that has been 
confirmed in multiple studies. However, with respect to 
patients with diabetes, data are inconsistent. This may 
be due a number of factors, including small numbers 
studied resulting in lack of power, or that patients with 
chronic hyperglycaemia are protected somewhat by 
glycaemic excursions during acute illness. Research 
is warranted to further understand whether GV is 
harmful in patients with pre-existing diabetes. 
RATIONALE FOR PERSONALISED 
THERAPY AND THAT THE HARM 
FROM EACH OF THESE DOMAINS MAY 
VARY ACCORDING TO PRE EXISTING 
PHYSIOLOGY
Diabetes is known to be associated with a large burden 
of illness in the outpatient setting and is associated 
with increased mortality[72]. Paradoxically, as discussed, 
multiple studies exist suggesting that acute hyper-
glycaema in critically ill patients without diabetes 
(i.e., patients with CIAH) is associated with increased 
mortality and morbidity when compared to those 
with known diabetes[73]. There is growing evidence 
that chronic hyperglycaemia may lead to cellular 
conditioning, and that in fact, may be protective 
against acute hyperglycaemia mediated damage 
during an episode critical illness[1]. These outcomes 
suggest that current target glucose levels in patients 
naïve to hyperglycaemia, or those suffering from CIAH, 
may be harmful to those with chronic hyperglycaemia 
or poorly controlled diabetes.
CONCLUSION
This review articulates the need for further research 
to be done to identify the ideal glucose targets in 
critically ill patient with pre-existing diabetes. Not only 
does hyperglycaemia occur frequently in this group, 
but, recent data suggests that targeted blood glucose 
concentrations may benefit from consideration of a 
patient’s premorbid glucose state. 
Our recommendations are to avoid treating patients 
with diabetes as a homogenous group. Treatment of 
the critically ill patient with type 2 diabetes should 
be personalised to their internal milieu. There is 
preliminary evidence suggesting that higher blood 
glucose concentrations (e.g., up to 14 mmol/L) in 
patients with uncontrolled type 2 diabetes may not be 
702 June 10, 2015|Volume 6|Issue 5|WJD|www.wjgnet.com
Table 7  Observational studies and outcomes related to hypoglycaemia (chronological order)
Ref. Year Study pts Study point Non diabetic patients Diabetic patients Overall message
Krinsley and 
Grover[60]





associated with septic shock. 
Renal insufficiency, mechanical 
ventilation, illness severity and use 
of ITT
Associated with inc risk 
of severe hypoglycaemia 
(P < 0.01)
DM had no association 
with mortality 
Mortality in severe 
hypoglycaemia cohort 56% vs 
control cohort 40%, P < 0.01
Egi et al[61] 2010     4946 Hypoglycaemia 
vs risk of death in 
critically ill patients
Mild or moderate hypoglycaemia 
was associated with mortality in 
critically ill patients
Mortality increases as severity of 
hypoglycaemia increases
Diabetic patients more 
likely to suffer from 
insulin-associated 
hypoglycaemia
22% of total patients had one 
episode of hypoglycaemia
Hospital mortality: 
hypoglycaemic cohort 37% vs 
control cohort 20%, P < 0.01
Krinsely et al[33] 2011     62401 Mild hypoglycaemia 
(blood glucose level 
< 3.9 mmol/L) vs 
risk of mortality in 
critically ill patients.
Mild hypoglycaemia was associated 




and mortality was 
independent of diabetic 
status
Inc severity of hypoglycaemia 
was associated with inc risk of 
mortality
Hypoglycemic patients had 
higher mortality regardless of 
diagnostic category and ICU LOS
Krinsley et al[32] 2013 44964 Hyperglycaemia, 
hypoglycaemia, and 
glycemic variability 
vs mortality (and 
how DM effects this)
Inc mortality with higher mean 
blood glucose (≥ 7.8 mmol/L)
Dec mortality with lower blood 
glucose (4.4-7.8 mmol/L)
Inc mortality with mean 
blood glucose between 
4.4-6.1 mmol/L
Dec mortality when 
blood glucose were 
higher (6.2-10 mmol/L)
Hyperglycaemia, 
hypoglycaemia, and increased 
glycemic variability are 
independently associated with 
mortality in ICU patients
Diabetic status tempers these 
relations
1Contains partial data from one prospective RCT (Glucontrol trial) and complete data from two observational cohorts (United States and The Netherlands). 
Inc: Increased; Dec: Decrease; LOS: Length of stay.
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